GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 15, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on October 15, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing details transactions in the company's own shares.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker for share purchases
- October 15, 2025 (date) — Date of announcement and filing
FAQ
What specific number of GSK plc ordinary shares were purchased?
The filing states that a 'following number' of shares were purchased, but the exact quantity is not specified in the provided text.
Who acted as the broker for these share purchases?
BNP Paribas SA acted as the broker for the Company's share purchases.
What is the nominal value of GSK plc's ordinary shares?
The ordinary shares of GSK plc have a nominal value of 31 1/4 pence each.
What type of report is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does GSK plc file annual reports under Form 20-F or 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Stats: 3,074 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-15 06:17:53
Filing Documents
- a3746d.htm (6-K) — 3319KB
- 0001654954-25-011786.txt ( ) — 3320KB
From the Filing
IN OWN SHARES a3746d UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:        14 October 2025 Aggregate number of ordinary shares of  31¼  pence each purchased:              270,000 Lowest price paid per share (GBp):             1,625.50p Highest price paid per share (GBp):             1,649.00p Volume-weighted average price paid per share (GBp):              1,641.67p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 3,514,000 ordinary shares.   Following the above purchase, the Company will hold 250,978,844 ordinary shares in treasury and have 4,064,434,985 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,064,434,985. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.17 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases Shares purchased:     GSK plc (ISIN: GB00BN7SWP63) Date of purchases:      14 October 2025 Investment firm:         BNP Paribas SA   Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   25,122   1,649.00p   1,627.00p   1,642.39p   CHIX   77,220   1,649.00p   1,625.50p   1,641.39p   XLON   167,658   1,649.00p   1,625.50p   1,641.69p       Individual transactions: Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   351   1628.0   XLON   14-Oct-2025   08:00:07   20251014147957693   646   1628.0   XLON   14-Oct-2025   08:00:07   20251014147957695   156   1627.0   BATE &